Novartis weekly recap: Avidity $12B deal and trial setbacks
Recap highlights Novartis’ strategy including buying Avidity for $12B and clinical trial setbacks, alongside governance activism and a reported HSBC price-target lift.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.